Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2016 07:30 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference

Rockville, MD, May 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
April 27, 2016 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of First Quarter 2016 Financial Results Conference Call

ROCKVILLE, Md., April 27, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, May 4, 2016, the Company will release its financial results for the quarter...
April 19, 2016 09:05 ET | Source: MacroGenics, Inc.

MacroGenics Presents Data from Five Preclinical Programs at AACR Annual Meeting 2016

ROCKVILLE, Maryland, April 19, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
April 06, 2016 07:00 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the 15th Annual Needham Healthcare Conference

Rockville, MD, April 06, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
March 16, 2016 16:31 ET | Source: MacroGenics, Inc.

MacroGenics Announces Five Posters at AACR Annual Meeting 2016

ROCKVILLE, Maryland, March 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative...
March 07, 2016 19:30 ET | Source: MacroGenics, Inc.

Data from MacroGenics’ Preclinical Studies of MGD009 Presented at Keystone Symposia’s Antibodies as Drugs (X2) Conference

MGD009 is a bispecific DART molecule that targets B7-H3 and CD3 Redirected T-cell killing of multiple B7-H3-expressing tumor cell lines observed in vitro Dose-dependent inhibition of tumor growth...
February 29, 2016 16:00 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and 2015 Financial Results

Eight molecules in clinical development, including six in immuno-oncology Multi-national Phase 1b/2 gastric cancer study initiated evaluating the combination of margetuximab and...
February 16, 2016 07:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Fourth Quarter and Full Year 2015 Financial Results Conference Call

ROCKVILLE, Md., Feb. 16, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
February 04, 2016 18:00 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the LEERINK Partners 5th Annual Global Healthcare Conference

Rockville, Md., Feb. 04, 2016 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
December 02, 2015 16:30 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the Oppenheimer 26th Annual Healthcare Conference

ROCKVILLE, Md., Dec. 02, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...